Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Pharmaceutical Industry

Politics

House poised to pass bill critical for drug industry; the Senate may be a slog

By Erin Mershon

Politics

Under fire from Trump, drug industry lands Oval Office meeting on Tuesday

By Dylan Scott

advertisement

Biotech

Biopharma expects a lot of M&A this year

By Meghana Keshavan

advertisement

Politics

The drug industry’s stake in Trumpcare is bigger than you think

By Dylan Scott

Business

Drug prices don’t budge even after pressure from Congress

By Associated Press

First Opinion

Election verdict: Pharma needs a new prescription

By Dana Goldman and Darius Lakdawalla

Politics

Big Pharma’s big question: Is Trump friend or foe?

By Dylan Scott

advertisement

Politics

Prop 61: Californians appear to say no to lowering drug costs

By Rebecca Robbins

advertisement

Politics

Drug pricing fight in California turns nasty with ads tarring pharma execs as criminals

By Rebecca Robbins and Meghana Keshavan

The Pharmalot View

Californians can sock it to ‘greedy’ pharma. But will ballot vote bring down drug prices?

By Ed Silverman

Politics

In a tight race, one of pharma’s favorite senators gets a little help from his friends

By Sheila Kaplan

First Opinion

Waste from pharmaceutical plants in India and China promotes antibiotic-resistant superbugs

By Henry A. Waxman and Bill Corr

Pharmalot

The curious case of the $9,500 skin gel

By Ed Silverman

Business

The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes

By Damian Garde

Politics

Donald Trump’s trade talk is making the drug industry uneasy

By Dylan Scott

Politics

5 ways drug makers and the health care industry are shaping campaigns

By Sheila Kaplan

In the Lab

The race for a Zika vaccine is intense. But it may be missing the most important players

By Helen Branswell

Don't Miss

How biotech executives profit from legal insider trades

By Damian Garde

Biotech

There’s a possible cure for ‘bubble boy’ disease. It will cost $665,000

By Damian Garde

The Pharmalot View

The ‘gouge factor’: Big companies want transparency in drug price negotiations

By Ed Silverman

Business

Why Democratic convention viewers saw so many drug ads

By Rebecca Robbins

First Opinion

Say what you will about Donald Trump. He’s right about drug companies

By Charles D. Rosen

Don't Miss

Billionaire businessman Mark Cuban has something to say about drug prices

By Dylan Scott

Biotech

Could a molecular ‘on-off switch for agony’ lead to a safer painkiller?

By Damian Garde

Business

Drug and device makers find receptive audience at for-profit, Southern hospitals

By Charles Ornstein and Ryann Grochowski Jones — ProPublica

The Pharmalot View

Drug industry overstates impact of patent reviews on innovation

By Ed Silverman

Biotech

Post-Brexit, will the European Medicines Agency be homeless?

By Meghana Keshavan and Rebecca Robbins

Politics

Supreme Court’s ruling in patent case a blow to drug industry

By Dylan Scott

Biotech

It’s the war of the tchotchkes as drug makers vie for attention at biotech bash

By Damian Garde

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

Industry

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT

X